We are pleased to announce that Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan, President: Shiro Inui) and Beijing Tide Pharmaceutical Co. Ltd. (Beijing, China, General Manager: Liu Hongxing) have signed a license agreement on FiblastR Spray in China. Beijing Tide expects to launch the product in 2010.

Kaken has the worldwide right to develop, manufacture and sell human bFGF (basic fibroblast growth factor) products. Kaken will endeavor to globally develop bFGF products, at least partly in collaboration with its overseas partners, based on know-how of bFGF that it has accumulated through its R&D.